Navigation Links
American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillion's Ovarian Cancer Test, OVA1
Date:11/12/2013

in the study were required to predict whether ovarian masses were malignant or benign following clinical assessment. The clinical assessment stipulated physical examination and imaging, family history, and laboratory tests (including CA125, if used). OVA1 performance as a risk stratification test was compared with clinical assessment, Predicted and actual referral rates were analyzed and predictions were compared with final pathology results.

Clinical assessment correctly predicted 120 of 164 malignancies (73.2%), while 44 were mistakenly predicted to be benign (26.8%). Among three risk-stratification methods compared, OVA1 showed the highest sensitivity (148/164, or 90.2%). OVA1 sensitivity was significantly higher than either benchmark method: sensitivity of the mod-ACOG guidelines was 130/164 (79.3%) while CA125 sensitivity was 112/164 (68.4%). The number of malignancies incorrectly stratified as low risk by CA125, mod-ACOG and OVA1 was 52 (31.6%), 34 (20.7%) and 16 (9.8%), respectively.

OVA1 performance predicted an overall referral rate of 55.7%, slightly lower than the actual referral rate of 60.0% observed across all patients in the study. Despite the other risk stratification methods predicting lower overall referral rates, approximately 48-52% of patients rated as low risk were nevertheless referred in actuality. Reasons for these unexpected referrals were not evident.

"This study, focused on intended-use patients enrolled through 44 sites nationwide, found that OVA1 sensitivity was statistically superior to CA125 or the other risk stratification protocols examined," stated Dr. Donald Munroe, Vermillion's chief scientific officer and SVP of business development. "While high sensitivity and negative predictive value are diagnostic imperatives for presurgical ovarian cancer triage, the work also shed light on patient referral patterns with or without OVA1. Notably, the predicted OVA1 referral rate was compar
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Latin American Peripheral Vascular Device Market Will Expand Strongly To reach Revenues of $335 Million in 2022
2. ChanRx to Present Results of Phase IIb Study in Atrial Fibrillation at the 2013 American Heart Association Scientific Sessions
3. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
4. Gateway Analytical to Exhibit Pharmaceutical Forensic Services at the American Association of Pharmaceutical Scientist Annual Meeting in San Antonio
5. IRIDEX Promotes Timothy D. Buckley to Vice President of Marketing and North American Sales
6. NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
7. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
8. Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets
9. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
10. American Capital Commits $391 Million in the Combination of Cambridge Major Laboratories and AAIPharma Services
11. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Endo International plc (NASDAQ: ... quarter 2014 revenues of $719 million, an increase of ... $712 million. Endo reported net income of $21 million ... of $35 million in the second quarter of 2013.  ... net income for the three months ended June 30, 2014 ...
(Date:7/31/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced that the Company will receive a ... Asahi Kasei Pharma Corporation (Asahi Kasei). The payment ... a regulatory application to the Japanese Pharmaceutical and ... (collagenase clostridium histolyticum) for the treatment of Dupuytren,s ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- Recovery time ... cholesterol-lowering medications known as statins, according to a new ... drugs may affect the body,s inflammatory response, reducing the ... And that seemed to be particularly true among people ... become one of the most widely prescribed medications in ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
(Date:7/31/2014)... a unique protein that has the unusual property of destroying ... therefore be continually recreated and is no stable protein. The ... of coagulated blood. If you get a blood clot, it ... accumulated in a blood vessel, and therefore PAI-1 is extremely ... for helping people with a blood clot or other blood ...
(Date:7/31/2014)... 2014 Healthinsurancefacts.org has released a ... insurance plans by comparing quotes. , In order ... should consider comparing quotes. They can do this by ... simple questionnaire. , Clients should do proper research ... health insurance policies, and each of them can be ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... will host its first-ever event in New York on ... Eventi Hotel in Manhattan. , Featuring keynotes by ... Assemblyman Steve Katz (R-Yorktown), the event will include lunch ... Compassionate Care Act and the work NCIA is doing ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Breakthrough in understanding of important blood protein 2Health News:Breakthrough in understanding of important blood protein 3Health News:Comparing Health Insurance Quotes Can Help Clients Find Affordable Plans 2Health News:THURSDAY, AUG 7: First-Ever National Cannabis Industry Association Event in New York Will Feature Senator Savino, Assemblyman Katz, & Industry Leaders 2
... however , MONDAY, Nov. 9 (HealthDay News) -- After a ... of cancer recurrence in the affected breast, a new study ... increased risk of developing breast cancer, and experts have suspected ... increased risk of cancer recurrence at the site of the ...
... Nov. 9 Abt Associates continues to ... consulting and support services with three recently awarded contracts ... Agency,s (FEMA) Office of Regional Operations, the National Commission ... Transit Authority (WMATA). The value of the combined ...
... WASHINGTON, Nov. 9 The American Academy of Physician ... assistants (PAs) practicing in the United States, applauds the ... care reform bill, H.R. 3962, the Affordable Health Care ... this reform bill will ultimately lower the cost of ...
... release is available in French . Montreal, November 9, ... female. In human bodies trillions of cells are coupled, too, and ... these don,t come in twos, they are regrouped into indistinguishable clusters. ... and illness scientists have long searched for ways to splice ...
... the world suffer from cataracts. Thomas Kohnen of the ... surgery with the implantation of an artificial lens in ... ( Dtsch Arztebl Int 2009; 106[43]: 695�). ... In Germany alone, more than 600,000 cataract operations are ...
... reason why African Americans are not receiving kidney/pancreas transplants ... racial groups. Dr. Keith Melancon, director of kidney ... professor of surgery at Georgetown University Medical Center, and ... the American Journal of Transplantation . ...
Cached Medicine News:Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2
... True/Flex technology which has revolutionized the treatment ... unique fluted titanium construct was used in ... The biology of the tibia, with its ... presents special challenges to the healing process. ...
... 3080/3085 SP Bariatric Foot Extension provides extraordinary ... surgical capabilities for Amsco 3080 and 3085 ... Extension is rated for patients up to ... and easy attachment and full positioning capability. ...
... care you can provide to your patients, ... including innovative products, standardization and reimbursement guidelines, ... lavage systems deliver the performance needed for ... and foreign material. Each provides controlled pressure ...
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
Medicine Products: